Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223463 · ClinicalTrials.gov registry record · NA
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer
A NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Not yet
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT07223463: Clinical Trial NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT07223463 is a NA study that has not yet begun recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223463, a NA study, has not yet begun recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a tailored intervention can help make it easier for adolescents and young adults with cancer to take their medications. The main questions the researchers are trying to answer are: * Does the tailored intervention increase adherence? * Does the tailored intervention improve quality of life? * Does the tailored intervention reduce health care utilization? The researchers will compare the tailored intervention to a uniform standard of care intervention (an intervention designed to be similar to what is currently happening in clinical care) to see if the tailored intervention works to improve adherence. Participants will: * Use an electronic pill bottle or box to store their medication * Participate in intervention sessions * Complete surveys before the intervention, after the intervention, and 6-months later
Primary Outcome
Each participant will be given an electronic adherence monitoring device to store their medication. An electronic adherence monitoring device is a pill bottle or box with an embedded computer chip. The computer chip records each time the device is opened. These device openings, or actuations, will be compared with the patient's prescribed medication regimen to compute their adherence (defined as the percentage of doses taken as prescribed).
Interventions
- BEHAVIORAL Tailored Program
- BEHAVIORAL Feedback Program (Uniform Standard of Care)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2030-08-31 |
| Phase | NA |
What is known before NCT07223463 opens enrollment
NCT07223463 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Tailored Program is the first listed.
NCT07223463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07223463 about?
NCT07223463 is a clinical study titled "A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer". The goal of this clinical trial is to learn if a tailored intervention can help make it easier for adolescents and young adults with cancer to take their medications. The main questions the researchers are trying to answer are: * Does the tailored intervention increase adherence? * Does the tailore...
What is the current status of trial NCT07223463?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2026-09-01. Estimated completion is 2030-08-31.
What interventions are being tested in trial NCT07223463?
The interventions under investigation include: Tailored Program (BEHAVIORAL), Feedback Program (Uniform Standard of Care) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07223463?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07223463's enrollment target sits among peer trials
160 628th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI